Why Is OCULAR THERAPEUTIX I (OCUL) Stock Down Today?

Ocular Therapeutix stock fell 20.67% to $7.66 on Monday, marking one of its sharpest declines since February. The drop was driven by clinical updates from two competitors, Koda Biologics and 4D Molecular, which posted encouraging results for their wet age-related macular degeneration (AMD) treatments. These developments raised concerns about the competitive landscape for Ocular’s own wet AMD drug candidates.

What Happened

The selloff began after Koda Biologics and 4D Molecular shared updates on their respective Phase 3 trials, signaling potential advancements in the treatment of wet AMD. These developments cast doubt on Ocular’s market position and therapeutic pipeline, leading to a sharp sell-off in its shares. The company had recently announced the completion of a Pre-NDA meeting with the FDA for its investigational product AXPAXLI, but this positive news failed to offset the impact of the competitive updates. The stock has now fallen 26.3% over the past eight sessions, from $10.14 to $7.47.

What The Data Shows

Ocular Therapeutix has a market capitalization of $2.1 billion and remains unprofitable, with a trailing twelve-month EPS of -1.41 and revenue declining 8.1% year to date. The stock has traded between $6.23 and $16.44 over the past 52 weeks. In recent insider transactions, several executives including COO Donald Notman and Chief Development Officer Peter Kaiser sold shares totaling $333,000 over the last 90 days. The stock hit a fresh 52-week low on September 28, marking its 27th such occurrence.

What To Watch

Investors should monitor Ocular Therapeutix’s next steps in its regulatory process for AXPAXLI and any further developments in the wet AMD space from competitors. Coverage breadth and sentiment shifts will also be key indicators of near-term direction.